礼来公布Retatrutide关键心血管风险指标取得临床意义改善

美股速递
Mar 19

礼来公司最新研究数据显示,其研发的Retatrutide在关键心血管风险因素方面展现出具有临床意义的基线改善效果。该药物在多项心血管健康指标上均观察到显著进步,为心血管疾病治疗领域带来新的突破可能。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10